SynthesisInternational journal of molecular sciences2018
DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder.
Synthesis in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The association between prenatal famine, DNA methylation and mental disorders: a systematic review and meta-analysis.Clinical epigenetics · 2023Pooled it
- Dissecting the Epigenetic Changes Induced by Non-Antipsychotic Mood Stabilizers on Schizophrenia and Affective Disorders: A Systematic Review.Frontiers in pharmacology · 2020Pooled it
- Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder.Translational psychiatry · 2026Trial
- Integrated proteomic, transcriptomic, and epigenomic profiling identifies SRA1 as a novel therapeutic target for postpartum depression.Npj mental health research · 2026Article
- A longitudinal DNA methylation atlas and its link to brain structure and mental health.Molecular psychiatry · 2026Article
- An epigenetic framework for understanding contextual influences on neural and socio-emotional development: Narrative review and case-study of the oxytocin receptor.Developmental cognitive neuroscience · 2026Review
- Methylation levels in the GRIN2B promoter region are associated with bipolar disorder and its anxiety and insomnia symptoms.Experimental and therapeutic medicine · 2025Article
- Epigenetics and suicidal behavior in adolescents: a critical review.Epigenomics · 2025Review
- From Serendipity to Precision: Integrating AI, Multi-Omics, and Human-Specific Models for Personalized Neuropsychiatric Care.Biomedicines · 2025Review
- Impacts of Polyenvironmental Factors on DNA Methylation in Patients With Psychosis.Schizophrenia bulletin open · 2025Article
- Systemic inflammation, oxidative damage and neurocognition predict telomere length in a transdiagnostic sample stratified by global DNA methylation levels.Scientific reports · 2024Article
- DNA methylation may partly explain psychotropic drug-induced metabolic side effects: results from a prospective 1-month observational study.Clinical epigenetics · 2024Observational
- DNA methylation differences in genes associated with human personal disorders and deviant behavior.AIMS neuroscience · 2024Article
- The role of DNA methylation in progression of neurological disorders and neurodegenerative diseases as well as the prospect of using DNA methylation inhibitors as therapeutic agents for such disorders.IBRO neuroscience reports · 2023Review
- Epigenetic Signatures in Hypertension.Journal of personalized medicine · 2023Article
- Considerations toward an epigenetic and common pathways theory of mental disorder.Journal of psychopathology and clinical science · 2023Article
- Review
- Epigenetics and ADHD: Reflections on Current Knowledge, Research Priorities and Translational Potential.Molecular diagnosis & therapy · 2022Article
- Tissue-Specific Methylation Biosignatures for Monitoring Diseases: An In Silico Approach.International journal of molecular sciences · 2022Article
- DNA Methylation of the Oxytocin Receptor Across Neurodevelopmental Disorders.Journal of autism and developmental disorders · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
So far, genetic studies of treatment response in schizophrenia, bipolar disorder, and major depression have returned results with limited clinical utility. A gene × environment interplay has been proposed as a factor influencing not only pathophysiology but also the treatment response. Therefore, epigenetics has emerged as a major field of research to study the treatment of these three disorders. Among the epigenetic marks that can modify gene expression, DNA methylation is the best studied. We performed a systematic search (PubMed) following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA guidelines for preclinical and clinical studies focused on genome-wide and gene-specific DNA methylation in the context of schizophrenia, bipolar disorders, and major depressive disorder. Out of the 112 studies initially identified, we selected 31 studies among them, with an emphasis on responses to the gold standard treatments in each disorder. Modulations of DNA methylation levels at specific CpG sites have been documented for all classes of treatments (antipsychotics, mood stabilizers, and antidepressants). The heterogeneity of the models and methodologies used complicate the interpretation of results. Although few studies in each disorder have assessed the potential of DNA methylation as biomarkers of treatment response, data support this hypothesis for antipsychotics, mood stabilizers and antidepressants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.